Guardant Health Inc. (GH) shares surged 5.68% in pre-market trading on Friday, driven by a series of positive analyst actions.
JP Morgan raised its price target on Guardant Health to $135 from $130, while TD Cowen increased its target to $127 from $120. Barclays also lifted its target to $120 from $115. Additionally, William Blair reiterated its Buy rating on the stock.
These analyst upgrades reflect growing optimism about the healthcare company's prospects, contributing to the significant pre-market price movement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments